Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alzamend Neuro, Inc. ALZN

Healthcare  —  Biotechnology
1.83 0.01 0.55% as of 25 Sep
Market cap
$8.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Alzamend Neuro, Inc. (ALZN) Business Profile

Updated before January 2025

Company Overview

Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for neurodegenerative diseases and psychiatric disorders. Founded in 2016, the company is headquartered in Tampa, Florida. Alzamend’s mission is to bring hope to millions of patients and their families by addressing unmet medical needs in the field of neurodegeneration, with a particular focus on Alzheimer’s disease, bipolar disorder, and other related conditions.

The company was founded by Milton “Todd” Ault III, a seasoned entrepreneur and investor with a strong background in healthcare and technology. Under the leadership of its CEO, Stephan Jackman, Alzamend has assembled a team of experienced professionals in biotechnology, clinical research, and regulatory affairs. The company also collaborates with leading academic institutions and research organizations to advance its pipeline of innovative therapies.

Core Business Segments

Alzamend Neuro focuses on the development of therapeutic solutions for neurodegenerative diseases and psychiatric disorders. Its core business segments include:

1. Alzheimer’s Disease Treatments

Alzamend is actively developing two key product candidates aimed at addressing Alzheimer’s disease:

  • AL001: A lithium-based ionic cocrystal therapy designed to improve lithium delivery and reduce toxicity. AL001 is being developed as a treatment for Alzheimer’s disease, bipolar disorder, and other neurodegenerative conditions. The therapy is currently in clinical trials and has shown promise in preclinical studies.

  • AL002: A patented immunotherapy designed to stimulate the immune system to combat Alzheimer’s disease. AL002 targets amyloid-beta plaques, a hallmark of Alzheimer’s pathology, and aims to reduce their accumulation in the brain. This product is also in the early stages of clinical development.

2. Psychiatric Disorder Therapies

In addition to Alzheimer’s disease, Alzamend is exploring the potential of its product candidates to treat psychiatric disorders such as bipolar disorder and depression. The company’s lithium-based therapy, AL001, is being evaluated for its efficacy in stabilizing mood and reducing symptoms of psychiatric conditions.

3. Research and Development Services

Alzamend invests heavily in research and development (R&D) to advance its pipeline of innovative therapies. The company collaborates with academic institutions, contract research organizations (CROs), and other partners to conduct preclinical and clinical studies. This segment is critical to Alzamend’s long-term growth and success.

Business Model

Alzamend Neuro operates as a clinical-stage biopharmaceutical company, meaning it does not yet generate revenue from product sales. Instead, the company relies on funding from investors, grants, and partnerships to finance its operations and R&D activities. Alzamend’s business model is centered on:

  • Innovative Therapies: Developing novel treatments that address unmet medical needs in neurodegenerative diseases and psychiatric disorders.
  • Collaborative Partnerships: Partnering with academic institutions, research organizations, and pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Regulatory Approvals: Navigating the complex regulatory landscape to bring its products to market. Alzamend is focused on obtaining FDA approval for its product candidates.

Once its therapies receive regulatory approval, Alzamend plans to generate revenue through product sales, licensing agreements, and strategic partnerships.

Strategic Direction

Alzamend Neuro is committed to advancing its pipeline of innovative therapies and achieving long-term growth. The company’s strategic priorities include:

  • Advancing Clinical Trials: Alzamend is focused on progressing its product candidates, AL001 and AL002, through clinical trials to demonstrate their safety and efficacy.
  • Expanding Indications: The company is exploring additional indications for its therapies, such as bipolar disorder and depression, to maximize their potential impact.
  • Sustainability Goals: Alzamend is dedicated to conducting its operations in an environmentally and socially responsible manner. The company aims to minimize its environmental footprint and contribute to the well-being of patients and communities.
  • Global Expansion: Alzamend plans to expand its presence in international markets by seeking regulatory approvals and establishing partnerships with global pharmaceutical companies.

Competitive Landscape

Alzamend Neuro operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Biogen Inc.: A leading biotechnology company focused on neurological diseases, including Alzheimer’s disease. Biogen’s Aduhelm (aducanumab) is one of the first FDA-approved therapies targeting amyloid-beta plaques.
  • Eli Lilly and Company: A global pharmaceutical company developing donanemab, an investigational therapy for Alzheimer’s disease.
  • Cassava Sciences, Inc.: A clinical-stage biopharmaceutical company developing simufilam, a small-molecule drug candidate for Alzheimer’s disease.
  • Anavex Life Sciences Corp.: A biotechnology company focused on precision medicine for neurodegenerative diseases, including Alzheimer’s disease.

Alzamend differentiates itself through its innovative approach to lithium-based therapies and immunotherapy, as well as its commitment to addressing unmet medical needs.

Risk Factors

Like any clinical-stage biopharmaceutical company, Alzamend Neuro faces several risks, including:

  • Regulatory Risks: The company’s product candidates must undergo rigorous clinical testing and obtain regulatory approval before they can be marketed. Delays or failures in the approval process could impact Alzamend’s growth.
  • Market Dependence: Alzamend’s success depends on the commercial viability of its therapies. If its products fail to gain market acceptance, the company may struggle to generate revenue.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers for its clinical trials. Disruptions in the supply chain could delay product development.
  • Financial Risks: As a clinical-stage company, Alzamend does not generate revenue and relies on external funding. Limited financial resources could hinder its ability to advance its pipeline.

Recent Developments

Alzamend Neuro has made significant progress in recent months, including:

  • Clinical Trial Advancements: The company has initiated Phase I/IIa clinical trials for AL001 and is preparing to advance AL002 into clinical testing.
  • Partnerships: Alzamend has strengthened its collaborations with academic institutions and research organizations to accelerate the development of its therapies.
  • Intellectual Property: The company has secured additional patents for its product candidates, enhancing its competitive position.

Global developments, such as the COVID-19 pandemic, have highlighted the importance of addressing neurodegenerative diseases, as patients with these conditions are particularly vulnerable to the virus.

Investment Considerations

Investors considering Alzamend Neuro should weigh the following factors:

Strengths

  • Innovative Pipeline: Alzamend’s product candidates have the potential to address significant unmet medical needs in neurodegenerative diseases and psychiatric disorders.
  • Experienced Leadership: The company’s management team has a strong track record in biotechnology and clinical research.
  • Collaborative Approach: Alzamend’s partnerships with academic institutions and research organizations enhance its R&D capabilities.

Risks

  • Clinical and Regulatory Uncertainty: The success of Alzamend’s therapies depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Dependence: The company relies on external funding to finance its operations and may face challenges in securing additional capital.
  • Competitive Pressure: Alzamend operates in a crowded market with established players and emerging competitors.

Conclusion

Alzamend Neuro, Inc. is a promising clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases and psychiatric disorders. While the company faces significant risks, its strong pipeline, experienced leadership, and collaborative approach position it for long-term success. As Alzamend advances its clinical trials and seeks regulatory approvals, it has the potential to make a meaningful impact on the lives of patients and their families while delivering value to investors.